Health Problems

Reversing polycystic kidney disease

Hereditary and relatively common, polycystic kidney disease (PKD) has long been thought to be progressive and irreversible, condemning its sufferers to a long, slow and often painful decline as fluid filled cysts develop in the kidneys, grow and eventually rob the organs of their function. Once their kidneys fail, PKD patients often require dialysis several […]

Health Problems

A promising treatment for an incurable, deadly kidney disease

A potential treatment for polycystic kidney disease—a genetic disorder that causes the kidneys to swell with multiple cysts and can eventually lead to organ failure—has shown promising results in animal testing. A study describing the drug’s development and testing appears today in Nature Communications. The study shows an approximately 50 percent reduction in kidney size […]

Health Problems

Poor kidney function linked to higher cancer risk

A new study has uncovered a modestly higher cancer risk in individuals with mild to severe chronic kidney disease, driven primarily by skin (non-melanoma) and urogenital cancers. The findings, which appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN), do not prove a causal link between kidney dysfunction […]

Health Problems

New kidney research sheds light on harms of certain drugs

Scientists have identified an enzyme that is a “master regulator” of kidney function that if excessively suppressed, can trigger renal failure. Their findings have implications for the use of existing drugs and the development of new pharmaceuticals. As reported in Nature Communications, a global research team led by the University of Bristol studied how the […]

Medications

Reata Announces Clinical Trial Design for FALCON, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Autosomal Dominant Polycystic Kidney Disease

IRVING, Texas, Jan. 03, 2019 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) regarding the design of a Phase 3 clinical trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant […]